How Eli Lilly’s obesity drug Zepbound is poised to reshape pharma markets

How Eli Lilly’s obesity drug Zepbound is poised to reshape pharma markets

Submitted by admin on November 9, 2023 - 11:41pm
Source: 
Medical Marketing and Media
News Tags: 
Eli Lilly
tirzepatide
weightloss
Zepbound
Mounjaro
Headline: 
How Eli Lilly’s obesity drug Zepbound is poised to reshape pharma markets
snippet: 

Tirzepatide, the active ingredient in Lilly’s type 2 diabetes drug Mounjaro, has now been approved to treat obesity. What does it mean for the pharma industry?

Do Not Allow Advertisers to Use My Personal information